GLP-1 Advisor | One Day MD

Last updated: October 2026 Have you noticed hollow cheeks, deeper smile lines, more visible wrinkles or loose skin after losing weight with Ozempic, Wegovy, Mounjaro or another GLP-1-based medication? These changes are commonly called Ozempic face . The term describes an appearance rather than a formally defined disease. It generally refers to facial volume loss and skin laxity associated with substantial weight loss. Similar changes can occur following bariatric surgery, dietary weight loss and treatment with other weight-management medications. The good news is that several options may improve facial appearance. The important distinction is between preventing avoidable nutritional and muscle losses, replacing lost facial volume and tightening loose skin . These are different problems and do not respond equally to the same treatment. This guide reviews the available evidence, practical prevention strategies, hyaluronic acid fillers, collagen-stimulating biostimulators, e...

Updated October 2026 “Ozempic face” has become a popular term for facial hollowing, reduced fullness, wrinkles and looser-looking skin after substantial weight loss. Hair shedding and loose skin have also become common concerns among people taking GLP-1 medicines such as semaglutide and tirzepatide. The important question is whether these changes are caused directly by the medication or whether they are primarily consequences of losing a substantial amount of body fat. The evidence is more nuanced than social media suggests. Rapid or substantial weight loss can change facial fat compartments, skin tension and body composition. Hair shedding can occur during major weight loss and is commonly described as telogen effluvium . Current U.S. FDA labeling for Wegovy and Zepbound recognizes hair loss as an adverse reaction associated with weight reduction. By contrast, “Ozempic face” is not a formal diagnosis and there is not strong clinical evidence showing that Ozempic uniquely...